Our studies further focus on the mechanism downstream of ATF5, revealing ATF5 as a critical mediator of neuroblastoma metastasis, identifying BMF as a downstream effector of ATF5-mediated survival of CTC, and showing that drugging ATF5 with a CP peptide is effective in blocking neuroblastoma growth and metastasis. The gene discussed is CP; the disease is neuroblastoma.